Literature DB >> 1493083

A study of the interaction of omeprazole and warfarin in anticoagulated patients.

P Unge1, L E Svedberg, A Nordgren, H Blom, T Andersson, P O Lagerström, J P Idström.   

Abstract

1. Thirty-five patients on continuous therapy with warfarin were given omeprazole 20 mg once daily and placebo each for 3 weeks according to a two-centre randomised double-blind cross-over design. 2. Blood samples were obtained once weekly during the run-in and follow-up periods as well as during the first 2 weeks of each treatment period, and twice during the last week of each treatment period. Plasma concentrations of R- and S-warfarin were measured by h.p.l.c. and the anticoagulant effect was assessed using the Trombotest. 3. Twenty-eight patients were evaluated. The mean plasma concentration of R-warfarin was increased by 9.5% during omeprazole treatment compared with placebo, while that of S-warfarin, the more active isomer, was unaffected. The coagulation time was not significantly changed (106 s during omeprazole and 98 s during placebo). Corresponding TT-values (Trombotest) were 8.8 and 9.9 (NS).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1493083      PMCID: PMC1381452          DOI: 10.1111/j.1365-2125.1992.tb05656.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole.

Authors:  T Andersson; C Cederberg; G Edvardsson; A Heggelund; P Lundborg
Journal:  Clin Pharmacol Ther       Date:  1990-01       Impact factor: 6.875

2.  Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators.

Authors:  T Andersson; C G Regårdh; M L Dahl-Puustinen; L Bertilsson
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

Review 3.  Warfarin as a probe of cytochromes P-450 function.

Authors:  L S Kaminsky
Journal:  Drug Metab Rev       Date:  1989       Impact factor: 4.518

4.  Stereoselective interaction of omeprazole with warfarin in healthy men.

Authors:  T Sutfin; K Balmer; H Boström; S Eriksson; P Höglund; O Paulsen
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

5.  Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell.

Authors:  B Wallmark; A Brändström; H Larsson
Journal:  Biochim Biophys Acta       Date:  1984-12-19

6.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9.

Authors:  M E Veronese; P I Mackenzie; C J Doecke; M E McManus; J O Miners; D J Birkett
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

7.  Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+)ATPase.

Authors:  E Fellenius; T Berglindh; G Sachs; L Olbe; B Elander; S E Sjöstrand; B Wallmark
Journal:  Nature       Date:  1981-03-12       Impact factor: 49.962

Review 8.  Omeprazole drug interaction studies.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1991-09       Impact factor: 6.447

9.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes.

Authors:  P P Wang; P Beaune; L S Kaminsky; G A Dannan; F F Kadlubar; D Larrey; F P Guengerich
Journal:  Biochemistry       Date:  1983-11-08       Impact factor: 3.162

10.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily.

Authors:  M V Relling; T Aoyama; F J Gonzalez; U A Meyer
Journal:  J Pharmacol Exp Ther       Date:  1990-01       Impact factor: 4.030

View more
  23 in total

Review 1.  Drug interactions update: drugs, herbs, and oral anticoagulation.

Authors:  A K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2001-09       Impact factor: 2.300

Review 2.  Pharmacokinetic drug interaction profiles of proton pump inhibitors.

Authors:  Henning Blume; Frank Donath; André Warnke; Barbara S Schug
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Dose-dependent pharmacokinetics of warfarin in healthy volunteers.

Authors:  S Y King; M A Joslin; K Raudibaugh; H J Pieniaszek; I H Benedek
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

Review 4.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 5.  Safety of potent gastric acid inhibition.

Authors:  Carlos Martín de Argila
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.

Authors:  Jari J Lilja; Janne T Backman; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

Review 7.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 8.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

9.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

10.  Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.

Authors:  Benjamin D Gold; James W Freston
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.